Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors - A Phase I-II Sequential Chemotherapy Protocol of Bevacizumab (Avastin) Plus High-dose ICE (Ifosfamide - Carboplatin - Etoposide) Intensification

Trial Profile

Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors - A Phase I-II Sequential Chemotherapy Protocol of Bevacizumab (Avastin) Plus High-dose ICE (Ifosfamide - Carboplatin - Etoposide) Intensification

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Autologous stem cell therapy; Carboplatin; Etoposide; Filgrastim; Ifosfamide
  • Indications Germ cell and embryonal neoplasms
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TAXIF III
  • Most Recent Events

    • 23 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
    • 23 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
    • 30 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top